ORIC Pharmaceuticals, Inc. ORIC
9.00 USD +0.09 (+1.01%)
At closeNov 12, 2026, 4:05 AM EST
9.04 +0.04 +0.44%
Pre-market · Nov 12, 4:05 AM ET
8.84 Day range 9.15
7.23 52-week range 14.68
- YTD
- +10.02%
- 1 year
- -27.88%
News
globenewswire.com ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address…
benzinga.com BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target BTIG analyst Jeet Mukherjee reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $26 price target.
benzinga.com Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14 Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $17 to $14.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18 Stifel analyst Laura Prendergast maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $14 to $18.
benzinga.com ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and…
benzinga.com Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.
benzinga.com JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26 JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.